Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
-
If you are wondering whether Medline is attractively priced or getting ahead of itself, starting with a clear view of value can help you decide what its current share price really means.
-
Medline shares last closed at US$47.22, with returns of 7.6% over 7 days, 13.9% over 30 days and 16.2% year to date, which has naturally raised questions about what is already priced in and what might still be on the table.
-
Recent market attention on Medline has been shaped by ongoing coverage of the company as a Medical Equipment stock on the Nasdaq and its place in investors' watchlists as they reassess healthcare names. This article was prompted to provide evergreen context so you can see how Medline stacks up on value, beyond just short term share price moves.
-
On Simply Wall St's 6 point valuation checklist, Medline scores 1 out of 6 . The sections that follow will walk through what that score reflects across different valuation approaches, and then finish with a broader way to think about what a fair price could mean for your own decision making.
Medline scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown .
Approach 1: Medline Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model takes estimated future cash the company could generate and discounts those amounts back to today using a required return, to arrive at an estimate of what the business might be worth right now.
For Medline, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest reported free cash flow is about $1.33b. Analysts have provided forecasts out to 2030, with Simply Wall St extending those projections further using its own assumptions. For example, forecast free cash flow for 2030 is $3.27b, with each of the years in between discounted back to reflect the time value of money.
Adding these discounted cash flows together gives an estimated intrinsic value of US$50.81 per share. Against the recent share price of US$47.22, the model suggests Medline trades at roughly a 7.1% discount, which sits in the “close enough” zone rather than extremely cheap or clearly expensive.
Result: ABOUT RIGHT
Medline is fairly valued according to our Discounted Cash Flow (DCF) , but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Approach 2: Medline Price vs Earnings
For a profitable company, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings, which makes it a useful cross check against the cash flow based valuation above.
What counts as a “normal” P/E will usually reflect how quickly earnings are expected to grow and how risky those earnings are, with higher growth or lower perceived risk often lining up with higher P/E levels. Medline currently trades on a P/E of 33.1x, compared with the Medical Equipment industry average of 26.6x and a peer group average of 24.2x. On simple comparisons, the stock sits at a higher multiple than both its industry and peers.
Simply Wall St’s Fair Ratio is a proprietary estimate of what Medline’s P/E might be given factors such as its earnings growth profile, profit margins, size, industry and key risks. This tends to be more tailored than a basic peer or industry comparison because it adjusts for company specific strengths and weaknesses. In Medline’s case, the Fair Ratio sits close enough to the current 33.1x P/E, which points to the stock being roughly in line with what that framework suggests.
Result: ABOUT RIGHT
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies .
Upgrade Your Decision Making: Choose your Medline Narrative
Earlier it was mentioned that there is an even better way to think about valuation, so it is worth introducing Narratives, which let you attach a clear story to your numbers by linking your view on Medline’s future revenue, earnings and margins to a financial forecast and then to a fair value estimate. On Simply Wall St’s Community page, millions of investors share Narratives that set out their assumptions and produce a Fair Value that can be compared directly with the current share price to help decide whether Medline looks appealing right now or worth watching for later. Narratives are kept fresh because they update automatically when new information such as earnings releases or news is added to the platform, so your story and numbers stay aligned without extra effort. For example, one Medline Narrative might assume a higher fair value and stronger revenue growth than another Narrative that uses more conservative revenue and margin assumptions, which shows how differing views can lead to very different price signals from the same company.
Do you think there's more to the story for Medline? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MDLN .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
